After decades of waiting, late-stage therapies may penetrate the COPD market this year

Therapies for chronic obstructive pulmonary disease (COPD) have been in continual development for decades to reduce exacerbations and the symptom load of the disease.

Of the nine late-stage pipeline agents that are currently in development for COPD globally, Sanofi/Regeneron’s Dupixent and Verona’s ensifentrine are close contenders trying to gain approval and entry in the market this year after positive Phase III clinical trial data was presented to the US Food and Drug Administration (FDA).